Lung cancer immunotherapy: progress, pitfalls, and promises
Abstract Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resist...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01740-y |
| _version_ | 1797865430292889600 |
|---|---|
| author | Aritraa Lahiri Avik Maji Pravin D. Potdar Navneet Singh Purvish Parikh Bharti Bisht Anubhab Mukherjee Manash K. Paul |
| author_facet | Aritraa Lahiri Avik Maji Pravin D. Potdar Navneet Singh Purvish Parikh Bharti Bisht Anubhab Mukherjee Manash K. Paul |
| author_sort | Aritraa Lahiri |
| collection | DOAJ |
| description | Abstract Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that a loss of effective anti-tumor immunity is associated with lung tumor evolution. Therapeutic cancer vaccines combined with immune checkpoint inhibitors (ICI) can achieve better therapeutic effects. To this end, the present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, the review also explores the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens. Finally, ongoing clinical trials, significant obstacles, and the future outlook of this treatment strategy are also highlighted to boost further research in the field. |
| first_indexed | 2024-04-09T23:07:49Z |
| format | Article |
| id | doaj.art-c436e1feacb34ca2a269478a80f12339 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-09T23:07:49Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-c436e1feacb34ca2a269478a80f123392023-03-22T10:35:22ZengBMCMolecular Cancer1476-45982023-02-0122113710.1186/s12943-023-01740-yLung cancer immunotherapy: progress, pitfalls, and promisesAritraa Lahiri0Avik Maji1Pravin D. Potdar2Navneet Singh3Purvish Parikh4Bharti Bisht5Anubhab Mukherjee6Manash K. Paul7Department of Biological Sciences, Indian Institute of Science Education and Research KolkataDepartment of Radiation Oncology, N. R. S. Medical College & HospitalDepartment of Molecular Medicine and Stem Cell Biology, Jaslok Hospital and Research CentreDepartment of Pulmonary Medicine, Postgraduate Institute of Medical Education and ResearchDepartment of Clinical Hematology, Mahatma Gandhi Medical College and HospitalDivision of Thoracic Surgery, David Geffen School of Medicine, University of California Los AngelesEsperer Onco Nutrition Pvt LtdDepartment of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los AngelesAbstract Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that a loss of effective anti-tumor immunity is associated with lung tumor evolution. Therapeutic cancer vaccines combined with immune checkpoint inhibitors (ICI) can achieve better therapeutic effects. To this end, the present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, the review also explores the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens. Finally, ongoing clinical trials, significant obstacles, and the future outlook of this treatment strategy are also highlighted to boost further research in the field.https://doi.org/10.1186/s12943-023-01740-yLung CancerSCLCNSCLCImmunotherapyNanomedicineCancer Vaccine |
| spellingShingle | Aritraa Lahiri Avik Maji Pravin D. Potdar Navneet Singh Purvish Parikh Bharti Bisht Anubhab Mukherjee Manash K. Paul Lung cancer immunotherapy: progress, pitfalls, and promises Molecular Cancer Lung Cancer SCLC NSCLC Immunotherapy Nanomedicine Cancer Vaccine |
| title | Lung cancer immunotherapy: progress, pitfalls, and promises |
| title_full | Lung cancer immunotherapy: progress, pitfalls, and promises |
| title_fullStr | Lung cancer immunotherapy: progress, pitfalls, and promises |
| title_full_unstemmed | Lung cancer immunotherapy: progress, pitfalls, and promises |
| title_short | Lung cancer immunotherapy: progress, pitfalls, and promises |
| title_sort | lung cancer immunotherapy progress pitfalls and promises |
| topic | Lung Cancer SCLC NSCLC Immunotherapy Nanomedicine Cancer Vaccine |
| url | https://doi.org/10.1186/s12943-023-01740-y |
| work_keys_str_mv | AT aritraalahiri lungcancerimmunotherapyprogresspitfallsandpromises AT avikmaji lungcancerimmunotherapyprogresspitfallsandpromises AT pravindpotdar lungcancerimmunotherapyprogresspitfallsandpromises AT navneetsingh lungcancerimmunotherapyprogresspitfallsandpromises AT purvishparikh lungcancerimmunotherapyprogresspitfallsandpromises AT bhartibisht lungcancerimmunotherapyprogresspitfallsandpromises AT anubhabmukherjee lungcancerimmunotherapyprogresspitfallsandpromises AT manashkpaul lungcancerimmunotherapyprogresspitfallsandpromises |